Abstract
Objective: The urinary proteome reflects molecular drivers of disease. The aim of this study was to construct a urinary proteomic biomarker predicting 1 year post ICU mortality. Design and method: In 1243 patients, the urinary proteome was measured on ICU admission, using capillary electrophoresis couple with mass spectrometry along with clinical variables, circulating biomarkers (BNP, hsTnT, active ADM, and NGAL) and urinary albumin. Methods included support vector modelling to construct the classifier, Cox regression, the integrated discrimination (IDI) and net reclassification (NRI) improvement and area under the curve (AUC) to assess predictive accuracy, and Proteasix and protein-proteome interactome analyses. Results: In the discovery (deaths/survivors, 70/299) and test (175/699) datasets, the new classifier ACM128, mainly consisting of collagen fragments, yielding AUCs of 0.755 (95% CI, 0.708–0.798) and 0.688 (0.656–0.719), respectively. While accounting for study site, clinical risk factors, hazard ratios in 1243 patients were 2.41 (2.00–2.91) for ACM128 (+1 SD), 1.24 (1.16–1.32) for the Charlson Comorbidity Index (+1 point), and > = 1.19 (P < = 0.022) for other biomarkers (+1 SD). ACM128 improved (P < = 0.0001) IDI (>= + 0.50), NRI (>= + 53.7) and AUC (>= + 0.037) over and beyond clinical risk indicators and other biomarkers. Interactome mapping, using parental proteins derived from sequenced peptides included in ACM128 and in-silico predicted proteases, including/excluding urinary collagen fragments (63/35 peptides), revealed as top molecular pathways protein digestion and absorption, lysosomal activity and apoptosis. Conclusions: The urinary proteomic classifier ACM128 predicts the 1-year post ICU mortality over and beyond clinical risk factors and other biomarkers and revealed molecular pathways potentially contributing to a fatal outcome.
Highlights
In high- and middle-income countries, millions of patients survive critical illness thanks to the highly specialized lifesustaining management in intensive care units (ICU)
Large cohort studies conducted in Canada [2], Australia [3], and the USA [1] demonstrated that Intensive care units (ICU) survivors followed up from 3 [1, 2] up to 15 [3] years experienced mortality rates 2 to 5 times higher than sex- and age-matched population controls
The current study aimed to develop a urinary proteomic classifier predictive of the 1-year mortality in ICU survivors
Summary
In high- and middle-income countries, millions of patients survive critical illness thanks to the highly specialized lifesustaining management in intensive care units (ICU). The number of patients who survive intensive care is growing fast, because of the demographic transition in aging populations [4] and the ongoing sophistication of critical care resulting in a lower in-ICU fatality rate [5,6,7]. Urinary proteomic profiling developed over the past 15 years into a state-of-the-art technology, which enables discovery of disease-specific multidimensional biomarkers indicative of molecular pathogenic processes [9, 10]. Along these lines, the current study aimed to develop a urinary proteomic classifier predictive of the 1-year mortality in ICU survivors. The French and European Outcome Registry in Intensive Care Unit Investigators (FROG-ICU; (NCT01367093) compiled the analyzed database [8, 11]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
